Sarc041 Verzenio Trial Highlights Pfizer, Not Lilly Opportunities
MSKCC's Sarc041 trial of Verzenio being discussed at #Asco26 plenary right now... actually a really interesting study, but more for $PFE $ONC CDK4 inhibitors than for $LLY, I reckon. I covered it here (pawyalled, soz) -> https://t.co/I7ZspUFfBI
Potency ≠ Durability: KRAS Inhibitors Finally Become Druggable
Our latest review from #ASCO26 explores KRAS inhibitors and why potency doesn't equal durability: https://t.co/5HBTWpGVH2 All is not what it seems. I still find it amazing what was one such an intractable target is now made druggable by a wide range of different...
Melatonin Cuts Radiation DNA Damage by One‑third
Melatonin has radioprotective effects☢️ In this 2020 clinical study, 5 healthy males aged 25–35 were given 100 mg of melatonin before exposure to 100 mGy of X-ray radiation (equivalent to multiple CT scans) - 1 hour after radiation: 33% reduction in DNA...
FDA Eyes PR Win with Rapid RVMD Approval
The FDA desperately needs a publicity win. Expect the $RVMD drug to be approved in record time.
Day 1 ASCO26 Trials: Real Findings, Gaps, Future Directions
Beyond the hype: some reflections on half a dozen key trials presented on Day 1 at #ASCO26... what the data actually shows, where it falls short, and what comes next: https://t.co/gCjrLDwtYp https://t.co/BRjJULU29d
Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy
Millions of women with breast cancer could be spared chemotherapy with a groundbreaking genomic test, according to the results of a trial that could transform healthcare guidelines worldwide.
Teclistamab Delivers 70% 18‑Month PFS vs 27% Standard
Nearly 70% of patients with relapsed multiple myeloma on teclistamab stayed free of disease progression at 18 months, compared with about 27% on standard treatment. The advantage persisted in heavily pretreated patients. myeloma
Makary's 'America First' Provisions Reach White House Review
Makary's 'America First' provisions did make it into the PDUFA VIII user fee draft deal (expected to be made public in July or August) and it's now under review at the White House https://t.co/64GUDv9kmA
VA Launches MDMA Trial; Psilocybin Shows Fast, Lasting Relief
Veterans Affairs announces new MDMA clinical trial; Psilocybin’s antidepressant effects are both rapid and long-lasting https://t.co/T5eCTPW77O
Allogene CEO Resigns as Agios Drug Flunks Key Test
Allogene CEO to step down; Agios drug fails key test https://t.co/Uvdzw5pNqM $ALLO $AGIO $AZN $ABBV $BBIO
FDA Cancer Office, Not CBER, Blocked RP1 Approval
Whether or not you believe $REPL RP1 deserves to be approved or not, let's please be truthful about what has transpired so far: Richard Pazdur and others in the FDA's cancer office were responsible for RP1's initial rejection. They objected...
Pfizer Inks $600M Deal
$PFE #Asco26 splash: $600m u/f deal with $IVBXF to develop 12 cancer projects, incl ADCs & multispecifics (8 from Innovent, 4 from Pfizer). Projects/targets undisclosed though https://t.co/tVAGO73UOD
Ocrelizumab Cuts Disability Progression 30% in PPMS
In primary progressive MS, ocrelizumab was associated with a 30% lower risk of disability progression than placebo in a broad Phase III trial. Benefits were also seen in patients with advanced disease, though one subgroup stood out more. multiplesclerosis
FDA Bayesian Guidance Explained in New Video Presentation
New video presentation on the FDA Bayesian guidance: https://t.co/0wiz1JblkO #Statistics #Bayes #pharma #rct #clinicaltrials @fda @US_FDA
AI Agents Slash Months From Drug Development Timeline
Enjamb (@tryenjamb) puts AI agents across the entire drug program, from evidence synthesis to regulatory docs to statistical programming, cutting months off the path from preclinical to approval. https://t.co/kfq4DbjffL https://t.co/CLWjXVy6F5